Evidence map›Paper›PMID 38370809›Full record

ArticlebioRxiv : the preprint server for biology2024

Ultra-high efficiency T cell reprogramming at multiple loci with SEED-Selection.

Christopher R Chang, Vivasvan S Vykunta, Daniel B Goodman, Joseph J Muldoon, William A Nyberg, Chang Liu, Vincent Allain, Allison Rothrock, Charlotte H Wang, Alexander Marson and 2 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Christopher R ChangGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0003-3124-8773
Vivasvan S VykuntaGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0002-5409-8635
Daniel B GoodmanGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0003-3759-6883
Joseph J MuldoonGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0003-3784-3565
William A NybergGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0002-9982-1305
Chang LiuGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0009-0003-1294-9686
Vincent AllainGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0002-1068-7892
Allison RothrockGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
Charlotte H WangGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0001-7588-2077
Alexander MarsonGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0002-2734-5776
Brian R ShyGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0001-9569-3708
Justin EyquemGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0001-8262-1190

Funding

Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GERMAN, MICHAEL S · 2003 to 2019
$21.8M
Medical Scientist Training Program (T32 NRSA Training Grant)T32GM141323 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Aimee Kao · 2021 to 2026
$10.5M
Non-viral genome, epigenome, and transcriptome engineering for clinical CAR-T cell manufacturingK08CA273529 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian R Shy · 2022 to 2026
$1.2M
NCATS NIH HHS L30 TR002983NCI NIH HHS K08 CA273529NIDDK NIH HHS P30 DK063720NIGMS NIH HHS T32 GM141323
6 · The paper itself

Abstract

Multiplexed reprogramming of T cell specificity and function can generate powerful next-generation cellular therapies. However, current manufacturing methods produce heterogenous mixtures of partially engineered cells. Here, we develop a one-step process to enrich for unlabeled cells with knock-ins at multiple target loci using a family of repair templates named Synthetic Exon/Expression Disruptors (SEEDs). SEED engineering associates transgene integration with the disruption of a paired endogenous surface protein, allowing non-modified and partially edited cells to be immunomagnetically depleted (SEED-Selection). We design SEEDs to fully reprogram three critical loci encoding T cell specificity, co-receptor expression, and MHC expression, with up to 98% purity after selection for individual modifications and up to 90% purity for six simultaneous edits (three knock-ins and three knockouts). These methods are simple, compatible with existing clinical manufacturing workflows, and can be readily adapted to other loci to facilitate production of complex gene-edited cell therapies.

Identifiers

PMID38370809
PMCPMC10871224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.